Gastric Content in Fasting Volunteers and in Tirzepatide Users: an Observational and Cross-sectional Study
Recruiting
Observational Study
Full Stomach Status
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 30 (estimated)
- Sponsor
- Hospital Israelita Albert Einstein · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Introduction
Obesity and type 2 diabetes mellitus constitute a global public health problem. Medications with glucagon-like peptide-1 (GLP-1) receptor agonist activity are a modern therapeutic option for both diseases. Liraglutide, semaglutide, dulaglutide and tirzepatide are representatives of this drug class, whose mechanism of action results in delayed gastric emptying, reduced gastric motilit…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults aged 18 years or older.
* Individuals currently using tirzepatide.
* Individuals fasting for at least 8 hours for solids and 2 hours for clear liquids without residue.
Exclusion Criteria:
* Pregnant or postpartum individuals.
* Technical limitation for gastric ultraso…
Contacts